- Case details
- Status—ActionProcedural applicationCategoryOther procedural
- Parties
- Claimants
- Meril Italy srlOperating co.
Representatives- Emmanuel Larere-Cabinet Gide Loyrette Nouel AARPI
- Raphaëlle Dequiré-Portiersupporting-Cabinet Gide Loyrette Nouel AARPI
Respondents- Edwards Lifesciences CorporationOperating co.
Representatives- Boris Kreye-Bird & Bird LLP
- Siddharth Kusumakar-Powell Gilbert (Europe) LLP
- Tessa Waldron-Powell Gilbert (Europe) LLP
- Division
- Paris CD
- Judges
- —
- Technology
- InstrumentsMedical technology
- Language
- —
- First decided
- Feb 28, 2024
| Median days to first decision | |
|---|---|
| All UPC | 124 |
| Paris CD | Locked |
At the UPC: Meril Group (60 cases)·Edwards Lifesciences Group (57 cases)
This dispute contains 6 other proceedings
UPC CoA 530/2024·UPC CoA 464/2024·UPC CFI 255/2023·CC 585030/2023·UPC APP 19959/2024 and 1 more
12 other defendants litigating the same or a related patent
UPC CFI 202/2025·UPC CoA 166/2025·UPC CoA 21/2025·UPC CoA 27/2025·UPC CFI 815/2024 and 7 more
- 2024-02-28
Summary: The Paris Central Division issued a procedural order in a revocation action concerning EP3646825 (Edwards Lifesciences v Meril Italy), addressing a request by Meril to allow a subsequent amendment to the patent by Edwards, in the context of compliance with R.30 RoP requirements for patent amendment applications.
Show the legal issues (3)
- Subsequent amendment to patent application (R.30 RoP)
- Admissibility of request to amend patent
- Amendment of case (R.263 RoP)
- 2024-02-27
Summary: The Paris Central Division ruled on Meril Italy's application to refuse admission of Edwards Lifesciences' subsequent request to amend patent EP 3 646 825, addressing the admissibility of post-deadline patent amendment requests under R.30(2) RoP.
Show the legal issues (2)
- admissibility of subsequent patent amendment request R.30(2) RoP
- leave to amend case R.263 RoP
- 2024-02-27%20CD%20Paris%20UPC_CFI_255-2023%20ORD_7283-2024%20App_7184-2024%20anonymized%20%281%29.pdf2024-02-27EN
- 3E509F6CA88E0F9BF9D2C0021F547EAE_en.pdf2024-02-28EN